Sana Biotechnology
Sana Biotechnology Inc is an American clinical-stage biopharmaceutical company developing engineered cell therapies for oncology, autoimmune diseases, and diabetes. The company advances its proprietary Hypoimmune (HIP) platform to escape immune rejection alongside fusogen technology for targeted cell delivery, advancing candidates including SC291 (CD19-targeted CAR-T) and UP421 (allogeneic islet cell therapy). Main revenue drivers currently consist of investment capital financing, research partnership receipts, and potential milestone licensing revenues as clinical trials progress. Sana Biotechnology targets medical oncologists, endocrinologists, clinical research hospitals, and patients across North America and Europe. The company holds an innovative market position in hypoimmune engineered cell therapy and targeted fusogen delivery technology. Headquartered in Seattle, Washington, Sana Biotechnology Inc is listed on the Nasdaq Stock Market.
2 of the funds FundTelligence covers report a position in Sana Biotechnology.
- Legal name
- SANA BIOTECHNOLOGY INC
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 2
Funds holding Sana Biotechnology
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.05 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.01 % (partially disclosed portfolio, June 2026)